Glucose-6-phosphatase α (G6Pase) deficiency, also known as von Gierke's Disease or Glycogen storage disease type Ia (GSD Ia), is characterized by decreased ability of the liver to convert glucose-6-phosphate to glucose leading to glycogen accumulation and hepatosteatosis. Long-term complications of GSD Ia include hepatic adenomas and carcinomas, in association with the suppression of autophagy in the liver. The G6pc−/− mouse and canine models for GSD Ia were treated with the pan-peroxisomal proliferator-activated receptor agonist, bezafibrate, to determine the drug's effect on liver metabolism and function. Hepatic glycogen and triglyceride concentrations were measured and western blotting was performed to investigate pathways affected by the treatment. Bezafibrate decreased liver triglyceride and glycogen concentrations and partially reversed the autophagy defect previously demonstrated in GSD Ia models. Changes in medium-chain acyl-CoA dehydrogenase expression and acylcarnintine flux suggested that fatty acid oxidation was increased and fatty acid synthase expression associated with lipogenesis was decreased in G6pc−/− mice treated with bezafibrate. In summary, bezafibrate induced autophagy in the liver while increasing fatty acid oxidation and decreasing lipogenesis in G6pc−/− mice. It represents a potential therapy for glycogen overload and hepatosteatosis associated with GSD Ia, with beneficial effects that have implications for non-alcoholic fatty liver disease.
Introduction
Glucose-6-phosphatase α (G6Pase, encoded by the G6PC gene) is a key enzyme for both gluconeogenesis and glycogenolysis. This enzyme is primarily expressed in liver and kidney and is responsible for maintaining normoglycemia through dephosphorylation of glucose-6-phosphate (G6P) to produce free glucose (1) . G6Pase deficiency in humans causes glycogen storage disease type Ia (GSD Ia) in which G6P accumulates in liver and kidney cells (2) . This leads to excessive accumulation of glycogen and triglycerides in the liver and progressive fatty liver disease that resembles the non-alcoholic fatty liver diseases (NAFLD) more commonly associated with diabetes and obesity.
GSD Ia is characterized by severe hypoglycemia during fasting (3) . Although dietary therapy consisting of strictly scheduled uncooked cornstarch consumption has reduced hypoglycemic episodes and extended the lifespan of GSD Ia patients (4) , there has been little progress in reversing the hepatocellular abnormalities associated with long-term complications of GSD Ia such as steatohepatitis and cirrhosis. Additionally, 70-80% of patients older than 25 have at least one hepatocellular adenoma (HCA) lesion (4) and have an increased risk for developing hepatocellular carcinoma (HCC) (5) . While the mechanisms behind HCA formation and HCA to HCC transformation are not fully understood, previous research has shown increased risk of HCC linked to steatosis in patients with non-cirrhotic NAFLD and type II diabetes (6) . Of note, glycogen and lipid over-accumulation can cause hepatocellular injury via both apoptosis (7) and inflammation (8) . This inflammation may also be partially responsible for the development of hepatic adenomas and carcinomas that occur in patients later in life (9) . The accumulation of hepatic lipids, i.e. hepatosteatosis, leads to the hepatic complications in GSD Ia; thus, reversing hepatosteatosis could be a strategy to treat or delay hepatic disease in GSD Ia.
Deficient macroautophagy ('autophagy') has been implicated in the pathogenesis of the GSD Ia liver (10) . Autophagy is a cellular process by which cells 'digest' their own components to provide energy and raw materials for survival. Autophagy was first discovered in electron microscopy studies of cells (11) , but recent advances in molecular and cell biology have provided new tools to study this process (12) . Autophagy is primarily regulated by energy state and cellular stress. Most notably, the nutrient sensing mTORC1 pathway can inhibit the formation of autophagosomes, whereas the energy sensing 5' AMP-activated protein kinase (AMPK) pathway promotes the formation of autophagosomes (13) . Autophagy also can promote catabolism of a variety of substrates within the liver. In particular, autophagy can remove triglycerides in fat droplets and generate fatty acids for β b-oxidation by mitochondria (14, 15) . Autophagy also has been linked to basal and thyroid hormone-stimulated fatty acid oxidation (14) to supply ATP required for gluconeogenesis. Furthermore, autophagy has been implicated in hepatic glucose production through its effects on gluconeogenesis and glycogenolysis (8, 16) . Autophagy is essential for maintaining blood glucose during fasting by degrading proteins for gluconeogenesis (17) . It also triggers the degradation of glycogen to glucose inside lysosomes (8) through the action of acid α-glucosidase (GAA) (16) . Thus, stimulating autophagy may enable hepatocytes to bypass the deficient G6Pase enzyme and to hydrolyze G6P to glucose in GSD Ia (8) .
We previously showed that autophagy was impaired in GSD Ia and that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, was able to induce autophagy and decrease hepatic glycogen and triglyceride levels in a GSD Ia mouse model (10) . However, given the potential toxicity of rapamycin, we examined whether a pan-peroxisomal proliferator-activated receptor (PPAR) agonist that activates all three PPAR isotypes-PPAR-α, PPAR-β/δ and PPAR-γ (18)-could increase autophagy and decrease hepatic triglycerides and glycogen. Previously, it was shown that a PPAR-α agonist, GW7647, was able to stimulate hepatic autophagy (19) . Upregulation of PPAR-α in the liver also increased hepatic autophagy and fatty acid betaoxidation (20, 21) . Additionally, both PPAR-α and PPAR-δ have been implicated in anti-inflammatory responses to hepatic steatosis (22, 23) . Given bezafibrate's ability to lower hepatic triglycerides and its potential to induce autophagy and limit inflammation, it was an attractive agent for reversing the hepatic metabolic abnormalities in GSD Ia. We thus evaluated bezafibrate's ability to stimulate autophagy and glycogenolysis in mice with GSD Ia and monitored its effects on hepatosteatosis.
Results
G6pc−/− mice have low body weight, hepatomegaly and hypoglycemia shortly after birth. Five-day bezafibrate administration of 5-day-old mice had no significant effect on body or liver mass either in G6pc−/− or unaffected mice in comparison with vehicle-treated controls (Supplementary Material, Fig. S1A and B). Likewise, bezafibrate had no effect on plasma triglyceride or free fatty acids concentrations in G6pc−/− mice (Supplementary Material, Fig. S1C and D) .
The hepatomegaly observed in G6pc−/− mice is caused primarily by an accumulation of triglycerides and glycogen in the liver (24) . To investigate whether bezafibrate could reverse these hepatocellular abnormalities, we performed biochemical assays as well as histological staining to measure triglyceride and glycogen content in the livers of G6pc−/− mice and unaffected controls. Bezafibrate administration from 5-10 days after birth led to decreased liver triglyceride concentrations in GSD Ia mice (P < 0.001), in comparison with vehicle treated controls (Fig. 1A) . However, glycogen concentration trended downward but was not significantly reduced by bezafibrate administration (Fig. 1B) . Oil Red O staining and hematoxylin-eosin staining of liver tissue demonstrated qualitative improvements in histology and liver triglyceride levels of G6pc−/− mice after bezafibrate administration ( Fig. 1C and Fig. D) . Thus, the accumulations of triglycerides in GSD Ia liver were significantly reduced after 5 days of bezafibrate treatment.
We next investigated the mechanism for reduced triglycerides and glycogen in the GSD Ia liver. We previously observed that autophagy is deficient in the livers of G6pc−/− mice (10) and contributes to hepatosteatosis (10) . To test whether bezafibrate was able to restore autophagy, we quantified the autophagy markers Microtubule-associated protein 1A/1B-light chain 3 (LC3)-II and p62. LC3-II is the phosphatidylethanolamineconjugated form of LC3-I (cytoplasmic protein), that is recruited to the autophagosomal membrane during autophagy induction; thus, it serves as a good marker for autophagosome number (25) . Bezafibrate administration increased LC3-II protein expression in both the livers of G6pc−/− and unaffected mice, compared with vehicle-treated controls ( Fig. 2A) , indicating that bezafibrate treatment increased autophagosome number. p62 is a scaffold protein that is degraded inside the autolysosome and its decrease serves as an autophagic flux marker. We observed that p62 protein levels were significantly decreased in G6pc−/− mice treated with bezafibrate, in comparison with vehicle-treated controls ( Fig. 2A) , indicating that bezafibrate increased autophagic flux. Along with increased LC3-II expression, these data indicated that 5 days of bezafibrate treatment increased autophagosome formation and restored autophagic flux (11) . Previous research attributed decreased autophagy in GSD Ia mice to lower levels of phosphorylated (activated) AMPK (10) . Western blotting of WT and G6pc−/− mice liver showed a trend toward increased p-AMPK protein expression relative to AMPK protein expression in bezafibrate-treated mice ( Fig. 2B ; P < 0.05 for unpaired t-test), suggesting that this was a factor involved in the restoration of autophagy in the GSD Ia mice. Unexpectedly, western blotting revealed a decrease in the ratio of phosphorylated adipose triglyceride lipase (ATGL) to non-phosphorylated ATGL in young WT mice, whereas ATGL has been reported as a downstream phosphorylation target of AMPK in cultured hepatocytes ( Fig. 2C; 26) . Importantly, phosphorylated mTOR protein expression, which causes reduced autophagy, was unchanged after bezafibrate treatment (Supplementary Material, Fig. S2 ). We next performed electronic microscopy to investigate the cargoes that were delivered for lysosomal degradation. In bezafibrate treated G6pc−/− liver, we observed lipid and glycogen inside autophagosomes or autolysosome structures (Fig. 2D) , suggesting that bezafibrateinduced autophagy delivered both lipids and glycogen as cargoes for lysosomal degradation.
We previously demonstrated defective mitochondria in GSD Ia liver, as evidenced by decreased mitochondrial biogenesis and content, abnormal ultra-structure and impaired oxidative phosphorylation (27) . To investigate the effect of bezafibrate on mitochondrial biogenesis, we examined the expression of PGC1α, a key co-factor involved in mitochondrial biogenesis and found that bezafibrate treatment increased PGC1α protein in G6pc−/− mice ( Fig. 3A ; P = 0.03 by unpaired t-test). Consistently, mitochondrial proteins, COXIV and TOMM20, trended higher following bezafibrate treatment in G6pc−/− mice ( Fig. 3B and Fig. C) , indicating that bezafibrate reversed the impairment of mitochondrial biogenesis in G6pc−/− mice.
Mitochondrial structure is intimately linked to its function. Consistent with increased PGC1α protein and mitochondrial biogenesis, G6pc−/− livers treated with bezafibrate had significantly more mitochondrial DNA than those treated with vehicle (Fig. 3D) . The organized cristae formed by folded-inner membrane is important for proper mitochondrial respiration. Accordingly, we examined mitochondrial ultra-structure by electronic microscopy. As shown in Figure 3E , mitochondria were distended and swollen in the G6pc−/− mice, and these changes were corrected by bezafibrate treatment. These results suggested that bezafibrate treatment not only restored mitochondrial biogenesis in G6pc−/− mice, but also improved mitochondrial structure.
We next focused on bezafibrate's effect on lipid metabolism, which is closely linked to autophagy. Western blotting of peroxisomal acylCoA oxidase (ACOX1) revealed significant increases and medium-chain acylCoa dehydrogenase (MCAD) trended higher following bezafibrate administration in livers from both G6pc−/− and unaffected mice in comparison to vehicle-treated controls ( Fig. 4A and Fig. B ). ACOX1 and MCAD are critical for mitochondrial and peroxisomal fatty acid β-oxidation, respectively (28) . Western blotting also revealed that fatty acid synthase (FAS) protein expression increased in vehicletreated G6pc−/− mice and normalized in livers from G6pc−/− mice treated with bezafibrate ( Fig. 4C) , suggesting that the accumulation of triglycerides was reversed by bezafibrate in G6pc−/− mice. Quantification of plasma acylcarnitines revealed significantly decreased total acylcarnitines in bezafibratetreated G6pc−/− mice compared with vehicle-treated controls as well as reductions in multiple acylcarnitine species generated from fatty acid β-oxidation (Fig. 4F ). These significant changes in FAS protein expression and plasma acylcarnitines after bezafibrate administration indicated that downregulation of lipogenesis and upregulation of fatty acid β-oxidation may be contributing to the decrease in triglyceride concentration found in the livers of G6pc−/− mice treated with bezafibrate for 5 days (29) .
Given evidence for autophagy induction, upregulation of fatty acid β-oxidation and decreased lipogenesis in mouse livers from G6pc−/− mice following bezafibrate treatment, we next investigated the mechanism by which bezafibrate could be regulating these processes. Bezafibrate is known to activate expression of PPAR-α, a nuclear transcription factor linked to autophagy and lipid metabolism (20, 30) . Cho et al. (31) recently showed that PPAR-α expression is suppressed in the livers of liver-specific G6pc−/− mice, likely contributing to hepatosteatosis. PPAR-α expression also was significantly suppressed in livers from vehicle-treated G6pc−/− mice in comparison with unaffected controls. Bezafibrate administration increased protein expression of PPAR-α almost 4-fold in the livers of G6pc−/− mice in comparison with vehicle-treated G6pc−/− mice ( Fig. 4D : student's unpaired t-test, P = 0.04). This trend was not mirrored in mRNA levels of PPAR-α (Fig. 4E ). Of note, bezafibrate administration for 5 days did not increase blood glucose concentrations in G6pc−/− mice above the limit of detection (Supplementary Material, Fig. S1E ). Although G6Pase is required for G6P dephosphorylation and release of free glucose, cells can circumvent this pathway through glycogen cycling by the action of glucosidases. Studies recently have shown that residual glucose production in G6pc−/− hepatocytes is due primarily to glucosidase activity (32) . Therefore, we performed activity assays for GAA, the enzyme that breaks down glycogen in the lysosome on liver homogenates to investigate differences between treatment groups. Results showed no significant change in GAA activity regardless of genotype, treatment or length of administration (Supplementary Material, Fig. S1F ). These findings suggest that increases in autophagy rather than increases in GAA contributed to the decrease in hepatic glycogen in G6pc−/− mice.
Early mortality of G6pc−/− mice complicates experiments with this model, because mice typically survive less than 2 weeks without gene replacement therapy (33) . Hepatomegaly was increased significantly by 10-day bezafibrate administration, as reflected by the increased liver weight relative to total body mass, in comparison with 10-day vehicle-treated G6pc−/− mice (Supplementary Material, Fig. S3A and B). Despite this trend, both liver and plasma triglyceride concentrations were normalized in G6pc−/− mice treated with bezafibrate for 10 days; however, there was no significant effect on liver glycogen levels (Fig. 5A-C) . Blood glucose was increased following bezafibrate treatment, in comparison with vehicle-treated G6pc−/− controls (Fig. 5D) . Although blood glucose concentrations were significantly lower than unaffected levels, individual measurements were above the lower detection limit for the glucometer (20 mg/dL), which was not observed in any of the 10-day vehicle-treated G6pc−/− mice or any G6pc−/− mice in any of the 5-day treated cohorts (Supplementary Material, Fig. S1E ). We performed GAA activity assays on liver homogenates to determine whether bezafibrate upregulated GAA enzyme activity and contributing to the elevated blood glucose levels in 10-day treated mice. GAA activity was increased in G6pc−/− mice livers treated with bezafibrate, in comparison with vehicle-treated G6pc−/− livers (Supplementary Material, Fig. S3C ), which suggests a role for lysosomal degradation of glycogen. Reverse transcriptase-polymerase chain reaction (RT-PCR) of 10-day bezafibrate-treated mouse livers revealed increased Acadm mRNA (the gene for MCAD) expression (Fig. 5E) .
The expression of genes related to abnormalities associated with hepatosteatosis was further evaluated following 10 Fig. S3K and L) . Thus, increases in several inflammation and ROS markers were detected in GSD Ia livers, and these abnormalities were partially corrected by bezafibrate treatment.
The long-term effects of bezafibrate was evaluated in dogs with GSD Ia. The GSD Ia canine model provides an outbred genetic model for the study of complications of GSD Ia (34). Three age-matched, male GSD Ia dogs were sustained by adeno-associated virus (AAV) vector-mediated gene therapy as described (35) , which partially reversed biochemical abnormalities without preventing the long-term risk for HCA and HCC (36) . Ultrasound examination following 1.2, 2.4 and 3.6 months of bezafibrate treatment revealed a more homogenous appearance of the liver after treatment, in comparison with baseline (Fig. 6B) . One dog demonstrated a hepatic mass that decreased in size after 1.2 months of bezafibrate treatment and could not be detected after 3.6 months of bezafibrate treatment (Fig. 6A and  Fig. B) . This finding was interpreted as a HCA, which decreased in size beyond detection. Normoglycemia during fasting was observed after 2.4 months of bezafibrate treatment in the 3 GSD Ia dogs (Fig. 6C) . Serum alanine transaminase (ALT) also was significantly decreased after 1.2 and 2.4 months of bezafibrate treatment (Fig. 6D) . Serum triglycerides and cholesterol decreased after 2.4 months of bezafibrate treatment without achieving statistical significance (Supplementary Material, Fig.  S4A and B); one dog had normal serum triglycerides prior to starting bezafibrate treatment reflecting the beneficial effects of gene therapy and no further decrease in triglycerides was observed in that dog. Thus, the addition of bezafibrate improved metabolic control following gene therapy, in association with the resolution of an apparent HCA.
Discussion
Defective autophagy and mitochondrial function are associated with GSD Ia (27) . We previously used the mTOR inhibitor, rapamycin, to restore autophagy in livers from GSD Ia mice and found that it improved lipid metabolism and liver function (10) . These studies showed that restoring hepatic autophagy pharmacologically may be an effective strategy to reduce lipid accumulation in GSD Ia. However, rapamycin administration itself has been associated with side effects, including insulin resistance and infections (37, 38) , raising concerns about its longterm clinical usage for GSD Ia or NAFLD.
PPAR-α is a nutrient-sensing nuclear receptor typically activated in the fasted state. Bezafibrate binds and activates PPAR-α to decrease lipogenesis and induce autophagy, fatty acid oxidation and mitochondrial activity. PPAR-α activation converts hepatic cells that are in a fed state that is rich in glycogen and triglycerides to a fasting state (Fig. 7 ). In the current study, we used bezafibrate, a pan-PPAR agonist, which is clinically used as lipid-lowering agent for the treatment of hyperlipidemia and demonstrated that bezafibrate improved hepatic lipid metabolism by targeting several metabolic defects in GSD Ia. We showed that bezafibrate stimulated hepatic autophagy in G6pc−/− mice by upregulating LC3-II and downregulating the p62 protein. Thus, bezafibrate treatment restored autophagy flux to enable excess lipid and glycogen to undergo lysosomal degradation and metabolism. Indeed, we observed significant decreases in triglycerides and glycogen in livers of G6pc−/− mice after 5 days of bezafibrate treatment. Bezafibrate also likely increased fatty acid oxidation and decreased lipogenesis by virtue of its effects on plasma acylcarnitines, as well as hepatic MCAD and FAS protein levels. In particular, bezafibrate corrected the increased expression of the lipogenic enzyme, FAS, in livers from G6pc−/− mice. Bezafibrate treatment also improved mitochondrial biogenesis and quality, as it increased PGC1a, ACOX1 and MCAD1 protein levels. Taken together, these results showed that bezafibrate may serve as a novel agent to reduce (D) Bezafibrate treatment significantly decreased plasma triglyceride concentration in G6pc−/− mice and produced measurable levels of blood glucose (E) compared with vehicle treated controls (glucose levels below lower detection limit for glucometer). (F) Acadm mRNA levels were elevated in G6pc−/− mice livers treated with bezafibrate. Group sizes are WT + Vehicle n = 5, WT + Bezafibrate n = 5, G6pc−/− + Vehicle n = 6, G6pc−/− + Bezafibrate n = 6. Mean +/− s.d. shown. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 from ANOVA (E, F) and Kruskal-Wallis testing (B, C, D). the effects of fatty liver and subsequent hepatic damage caused by long-term lipotoxicity.
We previously showed that decreased p-AMPK may be the cause of autophagy downregulation in GSD Ia, because of p-AMPK's role in activating autophagy and its ability to inhibit the suppression of autophagy by mTOR (10) . In particular, decreased hepatic p-AMPK and increased p-mTOR levels were observed in young GSD Ia mice compared with WT mice (10) . We previously showed that inhibition of mTOR by rapamycin was able to stimulate autophagy and decrease triglycerides. Here, we observed that bezafibrate increased phosphorylation of AMPK and autophagy (Fig. 2) but did not suppress mTOR activity (Supplementary Material, Fig. S2 ), suggesting that AMPK activation can be an alternative strategy to stimulate autophagy and reduce hepatic triglycerides and glycogen levels in GSD Ia. Additionally, there may be other cellular mechanisms leading to decreased autophagy in GSD Ia. Previous studies have attributed the autophagy impairment in GSD Ia to a decrease in the expression of SIRT1, leading to decreased activation of transcription factor FoxO (a transactivator of autophagic genes) and increased ATG acetylation and deactivation (31) . It also has been suggested that hepatosteatosis leads to an upregulation of apoptosis and subsequent inhibition of the autophagic pathway (7).
The benefits of bezafibrate that were demonstrated in GSD Ia livers included the reversal of negative effects that are associated with hepatosteatosis (Fig. 7) , all well described in recent reviews (20, 21, 39) . PPARα agonists including bezafibrate stimulate fatty acid oxidation and reduce accumulated triglycerides, in association with anti-inflammatory effects (20, 21) . Furthermore, hepatosteatosis suppresses mitochondrial function in association with increased ROS (39) . Markers for early inflammation and increased ROS were suppressed by bezafibrate administration (Supplementary Material, Fig. S3 ), in association with the induction of fatty acid oxidation and reduction of triglycerides ( Figs 1, 4 and 5) . Each of these effects was consistent with increased mitochondrial biogenesis that correlated with increased mitochondrial DNA content in the bezafibrate-treated GSD Ia liver (Fig. 3) . Intriguingly, continuing bezafibrate treatment for 10 days both decreased blood triglycerides and increased blood glucose, reversing major biochemical abnormalities of GSD Ia without preventing the early mortality that has been reported in absence of effective gene replacement therapy (33) . The stimulation of autophagy, at least early in the course of bezafibrate treatment (Fig. 2) , reversed the suppression of autophagy associated with GSD Ia (10, 31) Overall, treatment of GSD Ia mice with bezafibrate demonstrated reversal of hepatic abnormalities related to hepatosteatosis.
The animal models of GSD Ia require gene therapy to promote long-term survival, including both the homozygous G6pc−/− mouse or naturally occurring canine models (40) . While G6pc−/− mice were used to evaluate the short-term benefits of bezafibrate, we employed the canine model for GSD Ia to study longterm effects of GSD Ia, including the known occurrence of HCA and HCC (36) . Of note, gene therapy cannot prevent these tumors from developing because of the transient nature of AAV vectormediated gene therapy (41) . Studies have described 75-80% of adults over 30 years with GSD Ia have developed HCAs within These processes increase lipid metabolism, reduce glycogen accumulation and work to normalize liver tissue. Because hepatosteatosis and autophagy deficit add to the risk of GSD Ia patients developing HCA and HCC, addressing these cellular abnormalities can potentially help reduce the chance of negative, long term complications. Autophagy induction also has the potential to address hypoglycemia by circumventing G6Pase via glycogen cycling and glycogenolysis. their lifetime, with some transforming into HCC (42) (43) (44) (45) . Our group has reported aberrations of human chromosome 6, especially deletion of chromosome 6p, in GSD Ia patients with no mutations in the HNF1a gene, which contrasts with data from spontaneous HCA in non-GSD populations (46) . Others have further characterized HCA in GSD Ia patients as being 52% inflammatory HCA, 28% β-catenin-activated HCA or 20% unclassified HCA and also reported the absence of mutations in the HNF1a gene (42) (43) (44) (45) (46) (47) . Given these various etiologies, it is possible that HCA formation could be reversible. Interestingly, bezafibrate treatment in one dog not only reduced hepatic toxicity and hypoglycemia, but also decreased the size of a hepatic mass that was assessed by ultrasound examination (Fig. 6) . The resolution of HCAs after improvement in metabolic control has been reported previously in patients with GSD Ia (48) , and the current study supports that possibility.
This study provides additional support for the hypothesis that inducing autophagy has benefits in murine models for hepatosteatosis from GSD Ia (10,31) and NAFLD (14, 49) . We administered bezafibrate to young G6pc−/− mice that survived up to 2 weeks, which is the expected lifespan for complete G6pc−/− mice in absence of gene replacement therapy (33) . The main limitation of this study was the small number of mice studied that reflects the high mortality in this model for GSD Ia, which emphasizes the need for other studies to reproduce the demonstrated effects of PPAR agonism. Another recent study demonstrated similar benefits from reducing accumulations of hepatic triglycerides in adult liver-specific G6pc−/− mice treated with the PPARα agonist fenofibrate for 9 months (50). However, the reported effects of PPARα stimulation did not include the induction of autophagy, although PPARα has been implicated in the regulation of hepatic autophagy (19) . Further study will be required to address the question of whether pan-PPAR agonists have additional benefits in hepatosteatosis, in comparison with PPARα agonists.
Our study demonstrated the efficacy of bezafibrate as a new small molecule therapy for hepatosteatosis in GSD Ia, a rare orphan disease. NAFLD affects >40% of the US adult population and is associated with diabetes and obesity (51) . Its high prevalence places a high medical and economic burden on society, particularly since it has become a major cause for liver transplants. Our positive findings on the beneficial effects by bezafibrate on hepatosteatosis in GSD Ia suggest that it may be beneficial for patients with this condition. This study also provides information regarding beneficial effects of bezafibrate on hepatic metabolic physiology with potential implications in fatty liver, including NAFLD.
Materials and Methods

Study approval
All animals received human care and animal studies were approved by the Duke University Institutional Animal Care and Use Committee under the protocols A038-17-02, A211-14-08 and A168-17-07.
Reagents
Dimethyl sulfoxide (DMSO; D8418), Oil Red O (O0625) and amyloglucosidase (A1602) was purchased from Sigma-Aldrich (Sigma Chemical Co., St. Louis, MO). Pierce BCA Assay Kit (23225), optimal cutting temperature compound (4583), enhanced chemiluminescence substrate reagent (34095), 3-(N-morpholino) propanesulfonic acid running buffer (NP0001) and RadioImmunoPrecipitation Assay buffer (89900) were purchased from Thermo-Fisher (Thermo-Fisher Scientific, Waltham MA). Polyvinylidene fluoride membranes (1620177) were purchased from Bio-Rad (Bio-Rad Laboratories, Hercules, CA). Triglyceride Colormetric Assay Kits (10010303) and Free Fatty Acid Fluorometric Assay Kits (700310) were purchased from Cayman Chemical (Cayman Chemical Company, Ann Arbor, MI). Glutaraldehyde 3% sodium phosphate buffer (16539) was purchased from Electron Microscopy Sciences (Electron Microscopy Sciences, Hatfield, PA), and 10% neutral buffered formalin (89370-094) was purchased from VWR (VWR, Radnor, PA, USA). Bezafibrate was donated (Roivant Sciences, New York, NY). 50% dextrose (00409-6648-02) was purchased from Pfizer (Pfizer, New York, NY). The AlphaTrak glucometer and test strips (32107) were purchased from ADW Diabetes (ADW Diabetes, Pompano Beach, FL). The primary antibody recognizing PPARα (398394) was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Dallas, TX).
Mouse experiments
Carrier G6pc−/+ mice were bred to produce homozygous G6pc−/− offspring. G6pc−/− mice neonates are phenotypically distinct and easily distinguishable from their unaffected (+/− or +/+) littermates at about 3 days of age, whereupon they are given daily subcutaneous injections of 0.1 to 0.2 ml 10% dextrose. Bezafibrate was dissolved in a 1:10 DMSO:phosphate buffered saline solution (12 mg/kg) and administrated daily through intraperitoneal injection, starting at 5 days of age and continuing until either 9 or 14 days of age. The control group underwent a similar injection schedule with daily intraperitoneal injections of 1:10 DMSO:phosphate buffered saline vehicle. All G6pc−/− mice received dextrose daily, throughout the course of treatment until 24 h before sacrificing. Mice were sacrificed 24 h after the last day of treatment, whereupon blood glucose was measured and tissues were collected. Tissue from liver and kidney was frozen at −80
• C, flash frozen with OCT Tissue-Tek (Sakura Finetek USA, Inc., Torrance, CA) for tissue sectioning, saved in glutaraldehyde 3% sodium phosphate buffer (Electron Microscopy Sciences) for EM imaging and preserved in formalin (VWR).
Dog experiments
Three age-matched, male GSD Ia dogs were treated with AAV vectors encoding G6Pase to reverse hypoglycemia and promote survival as described (35) . This newly described cohort was injected with an AAV2 vector encoding human G6Pase (40) crosspackaged as AAV9 (AAV2/9-G6Pase) at 1 day of age (2 × 10 13 vp/kg). Additional vector treatments of different AAV serotypes were administered to treat symptoms of hypoglycemia at 2 and 3 months of age. At 2 months of age, each puppy was treated with AAV2/10-G6Pase (4.5 × 10 12 vp/kg), at 3 months of age at vector encoding canine G6Pase, AAV2/8-cG6PGH (33), was administered (2 × 10 12 vp/kg to 2 × 10 13 vp/kg, according to the degree of symptoms). These dogs were treated beginning at 2.4 years of age by oral administration of bezafibrate (4 mg/kg daily). Two dogs were treated for up to 3.6 months, while the third was treated for 2.4 months. Abdominal ultrasound examinations were performed monthly during this time. Blood glucose was monitored every 2 h during fasting for up to 8 h and analyzed using a point-of-care glucometer; glucose curve was stopped if a dog's blood glucose dropped below 50 mg/dl. The area under the curve (AUC) was determined using GraphPad Prism 7 (GraphPad Software, La Jolla, CA) for each glucose curve out to 8 h, if the glucose curve had to be stopped because of hypoglycemia, the value was recorded as 0 for that time point. Blood collected for biochemical data was collected after 4 h of fasting and submitted to Antech Diagnostics (Antech Diagnostics, Morrisville, NC, USA) for analysis.
Western blotting
Liver tissue samples were homogenized in RadioImmunoPrecipitation assay lysis buffer (Thermo-Fisher) and the protein concentration was determined via bicinchoninic acid assay (Thermo-Fisher). Laemmli sample buffer was added (250 mM/I Tris, pH 7.4, 2% w/v SDS, 25% v/v glycerol, 10% v/v 2-mecaptoethanol, 0.01% w.v bromophenol blue) and gel samples were boiled for 5 min and stored at −20 • C until SDS-PAGE were performed. Samples were ran on a SDS-polyacrylamide gel and transferred to a polyvinylidine diflouride membrane (Bio-Rad). Washing, blocking and antibody solutions were prepared in PBS with 0.1% Tween-20. Following washing, membranes were blocked for 1 h in 3% skim milk, incubated overnight at 4
• C with the primary antibodies, washed and reincubated for 1 h with the secondary antibody. After a final wash, ECL detection reagents (Thermo-Fisher) were added to the membrane and protein signal was read using a ChemiDoc imaging system (BioRad). Membranes were also imaged for β-actin control signal after stripping and re-blocking the membrane.
Biochemical assays
GAA activity and glycogen assays were performed on liver and kidney homogenates using previously described methods (52) . Triglyceride concentration in the blood and liver was determined using a colorimetric assay kit (Cayman Chemical) following the manufacturer's instructions. The free fatty acids concentration in the blood was determined using a fluorometric assay kit (Cayman Chemical) following manufacturer's instructions.
Oil Red O staining
Oil Red O staining was performed on OCT flash frozen liver samples stored at −80 • C, using previously described methods (53) and images were taken using a Zeiss PALM MicroBeam System (Zeiss, Thornwood, NY). 2 O was used as the mobile phase. Methylated acylcarnitine species were detected using a precursor ion of m/z 99 from 200 to 500 amu. Acylcarnitine species were quantified using the ion intensity ratio of analyte to the assigned deuterated internal standard for that analyte. Concentrations were determined using response factors generated by the calibration curves for the analyte or for the analyte closest in mass to the derivatized acylcarnitine species.
Acylcarnitine profiling
Acetyl-L-carnitine-(N-methyl-d 3 ) HCl (d 3 -C2), tetradecanoyl-L- carnitine-(N-methyl-d3) HCl (d 3 -C14), palmitoyl-L-carnitine- (N-methyl-d 3 ) HCl (d 3 -C16) (Sigma Chemical Co, St. Louis, MO); propionyl-L-carnitine-(N-methyl-d 3 ) HCl ((d 3 -C3) and L- glutarylcarnitine-d 6 chloride (d 6 -C5-DC) (Toronto Research Co, North York, ON, Canada); butyryl-L-carnitine-(N-methyl-d 3 ) HCl, octanoyl-L-carnitine-(N-methyl-d 3 ) HCl,
Electron microscopy
Fresh tissue was placed in fixative containing 2% paraformaldehyde and 3% gluteraldehyde in pH 7.4 phosphate buffer overnight at 4
• C. Tissue was washed once in PBS, followed by post-fixation with 1% osmium tetroxide. Samples were dehydrated in washes with ascending concentrations of alcohol, followed by embedding in Araldite. Sections were cut and stained with uranyl acetate and lead citrate. Imaging was performed on Olympus EM208S transmission electron microscope (Olympus Corporation, Shinjuku, Tokyo, Japan).
Periodic acid-Schiff staining for glycogen
Formalin-fixed, paraffin-embedded tissue sections was deparaffinized and hydrated to water, oxidized in 0.5% Periodic acid solution for 5 min. The slides were rinsed in distilled water and stained in Schiff reagent for 15 min, followed by counterstain with hematoxylin and eosin (H&E). The slides were mounted and the images were taken under bright field.
Statistics
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Statistical significance was determined by one-way ANOVA with Tukey's multiple comparisons test. Because of the low number of mice included in this study, data were assessed for normality distribution by Shapiro-Wilk normality testing before conducting statistical analyses. Data sets that did not meet this requirement were assessed using Kruskal-Wallis testing (non-parametric) with Dunn's multiple comparison test. The statistical significance of comparisons is indicated as * P < 0.05, * * P < 0.01, * * * P < 0.001 and * * * * P < 0.0001. P-values > 0.05 but <0.1 were also included on the graph.
Supplementary Material
Supplementary Material is available at HMG online. 
